Search

Magnetoencephalography (MEG) has been combined with machine learning techniques, to recognize the Alzheimer's disease (AD), one of the most common forms of dementia. However, most of the previous studies are limited to binary classification and do not fully utilize the two available MEG modalities (extracted using magnetometer and gradiometer sensors). AD consists of several stages of progression, this study addresses this limitation by using both magnetometer and gradiometer data to discriminate between participants with AD, AD-related mild cognitive impairment (MCI), and healthy control (HC) participants in the form of a three-class classification problem. A series of wavelet-based biomarkers are developed and evaluated, which concurrently leverage the spatial, frequency and time domain characteristics of the signal. A bimodal recognition system based on an improved score-level fusion approach is proposed to reinforce interpretation of the brain activity captured by magnetometers and gradiometers. In this preliminary study, it was found that the markers derived from gradiometer tend to outperform the magnetometer-based markers. Interestingly, out of the total 10 regions of interest, left-frontal lobe demonstrates about 8% higher mean recognition rate than the second-best performing region (left temporal lobe) for AD/MCI/HC classification. Among the four types of markers proposed in this work, the spatial marker developed using wavelet coefficients provided the best recognition performance for the three-way classification. Overall, the proposed approach provides promising results for the potential of AD/MCI/HC three-way classification utilizing the bimodal MEG data., (© 2021. The Author(s).)

Studies on developing effective neuromarkers based on magnetoencephalographic (MEG) signals have been drawing increasing attention in the neuroscience community. This study explores the idea of using source-based magnitude-squared spectral coherence as a spatial indicator for effective regions of interest (ROIs) localization, subsequently discriminating the participants with mild cognitive impairment (MCI) from a group of age-matched healthy control (HC) elderly participants. We found that the cortical regions could be divided into two distinctive groups based on their coherence indices. Compared to HC, some ROIs showed increased connectivity (hyper-connected ROIs) for MCI participants, whereas the remaining ROIs demonstrated reduced connectivity (hypo-connected ROIs). Based on these findings, a series of wavelet-based source-level neuromarkers for MCI detection are proposed and explored, with respect to the two distinctive ROI groups. It was found that the neuromarkers extracted from the hyper-connected ROIs performed significantly better for MCI detection than those from the hypo-connected ROIs. The neuromarkers were classified using support vector machine (SVM) and k-NN classifiers and evaluated through Monte Carlo cross-validation. An average recognition rate of 93.83% was obtained using source-reconstructed signals from the hyper-connected ROI group. To better conform to clinical practice settings, a leave-one-out cross-validation (LOOCV) approach was also employed to ensure that the data for testing was from a participant that the classifier has never seen. Using LOOCV, we found the best average classification accuracy was reduced to 83.80% using the same set of neuromarkers obtained from the ROI group with functional hyper-connections. This performance surpassed the results reported using wavelet-based features by approximately 15%. Overall, our work suggests that (1) certain ROIs are particularly effective for MCI detection, especially when multi-resolution wavelet biomarkers are employed for such diagnosis; (2) there exists a significant performance difference in system evaluation between research-based experimental design and clinically accepted evaluation standards.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Mass spectrometry-based discovery proteomics is an essential tool for the proximal readout of cellular drug action. Here, we apply a robust proteomic workflow to rapidly profile the proteomes of five lung cancer cell lines in response to more than 50 drugs. Integration of millions of quantitative protein-drug associations substantially improved the mechanism of action (MoA) deconvolution of single compounds. For example, MoA specificity increased after removal of proteins that frequently responded to drugs and the aggregation of proteome changes across cell lines resolved compound effects on proteostasis. We leveraged these findings to demonstrate efficient target identification of chemical protein degraders. Aggregating drug response across cell lines also revealed that one-quarter of compounds modulated the abundance of one of their known protein targets. Finally, the proteomic data led us to discover that inhibition of mitochondrial function is an off-target mechanism of the MAP2K1/2 inhibitor PD184352 and that the ALK inhibitor ceritinib modulates autophagy.

The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, non-receptor tyrosine kinases whose activities have been associated in the literature and the clinic with a variety of hyperproliferative diseases and immunological disorders. At the onset of the program, it was hypothesized that a JAK1 selective compound over JAK2 could lead to an improved therapeutic index relative to marketed non-selective JAK inhibitors by avoiding the clinical AEs, such as anemia, presumably associated with JAK2 inhibition. During the course of the JAK1 program, a number of diverse chemical scaffolds were identified from both uHTS campaigns and de novo scaffold design. As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chemical series. Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

A clinical trial pilot study, double-blinded, randomized, and controlled with a placebo to assess the effectiveness of oral doxycycline (200 mg, single dose) in preventing leptospirosis after high exposure to potentially contaminated water was performed in São Paulo, SP, Brazil. Confirmed cases were defined as those with leptospira IgM antibody and symptoms; asymptomatic cases were those presenting with IgM antibodies but no symptoms; and suspected cases were individuals with symptoms but no IgM antibody. Forty subjects were given doxycycline and 42 were given placebo. In the drug-treated group there were 2 confirmed cases, 11 asymptomatic cases, and 6 suspected cases. In the placebo group there were 5 confirmed, 6 symptomatic, and 5 suspected cases. Even though we found a protective association of doxycycline for confirmed leptospirosis cases (RR = 2.3) and seroconversion only (RR = 2.0), the association was not statistically significant because of the small number of individuals enrolled in this pilot study. We observed that the 22% of the volunteers already had IgM antibodies to leptospirosis at the first sampling. Finally, the attack rate to confirmed, asymptomatic, and suspected cases of Leptospirosis was 8.5%, 22%, and 13%, respectively, in this population.